-Relocation of Corporate Headquarters
-Presentation of Integrated Pipeline at BIO2019
In connection with the relocation of the corporate headquarters,
“We are happy to have Amit join the Mateon team to establish a strong finance and accounting organization. Amit brings with him over 20 years of strong financial, accounting and auditing experience to Mateon,” stated
Mr. Shah stated, “The opportunity to work with the leadership at Mateon on a new vision for building a strong finance and accounting infrastructure for Mateon, as well as growing the company through the development of the company's product portfolio, is exciting. I am equally excited to be contributing to building Mateon into a strong and growing biotech company and ultimately, a commercial organization. There are several promising therapies in our clinical pipeline that, if approved by the
Additionally, the company attended the 2019
“I feel a strong sense of conviction that TGF-beta therapeutics are coming of age, especially with the
OT-101 is a first-in-class RNA therapeutic targeting TGF beta that exhibited single-agent activity in relapsed/refractory cancer patients in clinical trial settings. In particular, the deep and durable objective responses achieved in patients with recurrent/refractory difficult-to-treat forms of brain tumors suggest that new treatment strategies leveraging the clinical anti-tumor activity of this first-in-class RNA therapeutic may favorably change the therapeutic landscape for many difficult-to-treat cancer types.
About the company’s Self-Immunization Protocol (SIP©)
The company’s self-immunization protocol (SIP©) is based on the novel and proprietary sequential treatment of cancers with OT-101 (an antisense against TGF-β2) and chemotherapies. This sequential treatment strategy is aimed at achieving effective self-immunization against a patients’ own cancer, resulting in robust therapeutic immune response and consequently better control of the cancer and improved survival. Prolonged states of being cancer-free have been observed in some patients with the most aggressive forms of cancer, raising a renewed hope for a potential cure. The use of OT-101 lifts the suppression of the patient’s immune cells around the cancer tissue, providing the foundation for the initial immune priming event, which is critical for a successful immune response.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans, and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, "estimate," "intend," "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the
Source: Mateon Therapeutics